Rappta Therapeutics

Executive Summary

Rappta Therapeutics is a preclinical biopharmaceutical company based in Helsinki, Finland, focused on developing first-in-class small molecules that reactivate protein phosphatase 2A (PP2A), a key tumor suppressor frequently inactivated in cancer. Founded in 2020, the company is currently in the lead-optimization stage, advancing a novel series of anti-cancer molecules toward candidate selection. PP2A reactivation represents a promising approach to address a broad range of oncology indications by restoring a natural brake on cell proliferation. Despite being early-stage, Rappta’s differentiated mechanism and targeted strategy position it as a potential player in the emerging field of phosphatase modulators. Given its preclinical status, Rappta has not yet disclosed total funding or valuation, but the company is actively progressing its pipeline. The next 12-18 months will be critical as it aims to select a development candidate, secure additional financing, and initiate IND-enabling studies. Success in these milestones could validate its platform and attract partnership interest. However, the inherent risks of early-stage drug development, including scientific uncertainty and capital requirements, temper the outlook. Vigilant execution and market conditions will determine Rappta’s trajectory toward clinical translation.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate nomination80% success
• TBDSeries A financing round60% success
• Q2 2027IND-enabling study initiation30% success